University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
689 Ergebnisse für "promising" unter University of Zurich
UZH - Mathematisch-naturwissenschaftliche Fakultät - Promising trea...
... Promising treatment prospects for invasive breast cancer Scientists from the University of Zurich ... UZH - Mathematisch-naturwissenschaftliche Fakultät - Promising treatment prospects for invasive ... UZH - Mathematisch-naturwissenschaftliche Fakultät - Promising treatment prospects for invasive ... UZH - Mathematisch-naturwissenschaftliche Fakultät - Promising treatment prospects for invasive ...
UZH - Faculty of Science - Promising treatment prospects for invasi...
... Promising treatment prospects for invasive breast cancer Scientists from the University of Zurich ... UZH - Faculty of Science - Promising treatment prospects for invasive breast cancer ... UZH - Faculty of Science - Promising treatment prospects for invasive breast cancer Home Main ... UZH - Faculty of Science - Promising treatment prospects for invasive breast cancer ...
ETH Entrepreneurship
https://ethz.ch/en/industry/entrepreneurship.html
8952 Schlieren, Wagistrasse 18
Excellence in entrepreneurship at ETH Zurich is driven by world-class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions.
ETH Entrepreneurship
Wagistrasse 18
8952 Schlieren
713 Ergebnisse für "promising" unter ETH Entrepreneurship
Neural Correlates of Three Promising Endophenotypes of Depression: ...
... Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study ... Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study ... Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study ... Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study ... Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study ...
08 – Nanomaterials Engineering Research Group | ETH Zurich
... 3 NH 3 PbBr 3 2 PbBr 3 perovskites, leading to one of the most promising semiconductor materials ... CH(NH 2 ) 2 PbBr 3 perovskites, leading to one of the most promising semiconductor materials for next ...
Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
1508 Ergebnisse für "promising" unter Somagenetix
Reactive stability of promising scalable doped ceria materials for ...
... Reactive stability of promising scalable doped ceria materials for thermochemical two-step CO2 ... Reactive stability of promising scalable doped ceria materials for thermochemical two-step CO2 ... Reactive stability of promising scalable doped ceria materials for thermochemical two-step CO2 ...
Organometallic Derivatization of the Nematocidal Drug Monepantel Le...
... Organometallic Derivatization of the Nematocidal Drug Monepantel Leads to Promising Antiparasitic ... Organometallic Derivatization of the Nematocidal Drug Monepantel Leads to Promising Antiparasitic ... Organometallic Derivatization of the Nematocidal Drug Monepantel Leads to Promising Antiparasitic ...
Bio-Technopark Schlieren-Zürich
8952 Schlieren, Wagistrasse 23
+41 76 336 99 44
mario.jenni@bio-technopark.ch
The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.
Bio-Technopark Schlieren-Zürich
Wagistrasse 23
8952 Schlieren
18 Ergebnisse für "promising" unter Bio-Technopark Schlieren-Zürich
Positive MAPLE data for abicipar, promising research data for Molec...
... Positive MAPLE data for abicipar, promising research data for Molecular Partners’ innovative ... Positive MAPLE data for abicipar, promising research data for Molecular Partners’ innovative ... https://www.bio-technopark.ch/en/news-en/positive-maple-data-for-abicipar- promising-research-data ... Positive MAPLE data for abicipar, promising research data for Molecular Partners’ innovative ...
Molecular Partners Receives Orphan Drug Designation for MP0250 for ...
... scientific and clinical data submissions from sponsors to identify and designate products as promising for ... rare diseases and to further advance scientific development of such promising medical products. Orphan ... identify and designate products as promising for rare diseases and to further advance scientific ... development of such promising medical products. Orphan drug designation provides incentives for sponsors to ...
Molecular Partners AG
http://www.molecularpartners.com
8952 Schlieren, Wagistrasse 14
+41 44 755 77 00
Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.
Molecular Partners AG
Wagistrasse 14
8952 Schlieren
23 Ergebnisse für "promising" unter Molecular Partners AG
Comments on: Molecular Partners reports promising initial safety an...
... Comments on: Molecular Partners reports promising initial safety and efficacy data from its ongoing ... phase 2 study of MP0250 in multiple myeloma Comments on: Molecular Partners reports promising initial ... Comments on: Molecular Partners reports promising initial safety and efficacy data from its ongoing ... https://www.molecularpartners.com/molecular-partners-reports- promising-initial-safety-and-efficacy ... Comments on: Molecular Partners reports promising initial safety and efficacy data from its ongoing ...
MP and Roche start collaboration on the DRP Technology - Molecular ...
... bacteria, DARPins are one of the most promising non-antibody scaffolds for in vitro and in vivo ... collaboration with Roche is another strong sign for the promising potential of Molecular Partners’ technology ... their very favorable production properties in bacteria, DARPins are one of the most promising non ... promising potential of Molecular Partners’ technology and confirms our efforts to remain a leader in the ...
InCephalo AG
8952 Schlieren, Wagistrasse 21
InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, also called C-Lock, retains biologics, that are applied locally behind the blood brain barrier, in the central nervous system (CNS) and once they leave the CNS, degrades them rapidly in the systemic compartment. Thereby it significantly improves local CNS therapy, a challenging task with regards to achieving high local concentration (for efficacy) and low systemic footprint (to reduce potential side effects). Especially the peripheral side effects still limit various promising candidates for the treatment of brain cancer or other neurological diseases.
InCephalo AG
Wagistrasse 21
8952 Schlieren
3 Ergebnisse für "promising" unter InCephalo AG
InCephalo Therapeutics
... effects still limit various promising candidates for the treatment of brain cancer or other neurological ... currently applying the C-Lock technology on a variety of established and promising new targets for novel ... still limit various promising candidates for the treatment of brain cancer or other neurological ... is currently applying the C- Lock technology on a variety of established and promising new targets ...
rqmicro AG
8952 Schlieren, Brandstrasse 24
+41 44 512 51 51
rqmicro’s separation and detection technology for microbiological tests in the water and food industry delivers reliable, quantitative and cost-effective results in less than 2 hours.
rqmicro AG
Brandstrasse 24
8952 Schlieren
Topadur Pharma AG
8952 Schlieren, Grabenstrasse 11a
A team dedicated to develop innovative speciality medication for the treatment of severe wound-healing problems enabling significant improvements of patients quality of life. TOPADUR’s lead R&D programs are local active, highly potent, dual mode of action drugs. TOPADUR’s unique development candidates #3;work on validated drug targets resulting in higher than average clinical success chances.
Topadur Pharma AG
Grabenstrasse 11a
8952 Schlieren
13 Ergebnisse für "promising" unter Topadur Pharma AG
Vision | Topadur
... promising significant return of investment Serving patients with highly effective and save products ... , investors and employees. Assets, experience and dedication promising significant return of investment ...
TOPADUR Pharma AG ranked #58 in the 2016 TOP 100 Swiss Startups lis...
... promising Swiss startups are picked by top startup experts. Only 1 year after funding, TOPADUR Pharma AG ... promising Swiss startups are picked by top startup experts. Only 1 year after funding, TOPADUR Pharma AG ... achieved rank #58 in the 2016 list of the 100 most promising Swiss startups. Please check for more details ...
CUTISS AG
8952 Schlieren, Grabenstrasse 11
+41 44 244 36 60
info@cutiss.swiss
After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.
CUTISS AG
Grabenstrasse 11
8952 Schlieren
89 Ergebnisse für "promising" unter CUTISS AG
Swiss RTS television reportage for T.T.C. – CUTISS
... to hear from our CIO Vincent about the promising potential of automation to scale up skin tissue ... Vincent about the promising potential of automation to scale up skin tissue bioengineering. The CUTISS ...
4. September 2019 – CUTISS
... event where the most promising Swiss startup CEOs, investors, and corporate executives gain deep ... . Each year since 2011, the 100 most innovative and promising Swiss startups are picked by a jury of 100 ... TOP 100 Swiss Startup Award is the yearly reference event where the most promising Swiss startup CEOs ... promising Swiss startups are picked by a jury of 100 leading investors and startup experts. The selected TOP ...
CSL Vifor
https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor
8952 Schlieren, Wagistrasse 25
+41 58 851 80 00
Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.
CSL Vifor
Wagistrasse 25
8952 Schlieren
136 Ergebnisse für "promising" unter CSL Vifor
Early Careers at CSL
... your degree, it's never too soon to consider CSL for your Promising FUTURE. Find yours here ... your degree, it's never too soon to consider CSL for your Promising Future! Early Careers at CSL ... CSL for your Promising FUTURE. Find yours here. Apprenticeships Prepare for your professional future ...
CSL Annual Report 2022 – Page 40
... US) Providing promising futures for employees At CSL, we want all employees to pursue their career ... aspirations and reach their potential. We launched our Promising FUTURES channel to reflect our commitment to ... .] CSL’s Disability Profile (Germany an US) Providing promising futures for employees At CSL, we want all ... employees to pursue their career aspirations and reach their potential. We launched our Promising FUTURES ...
